Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features
- 15 February 2012
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 77 (1), 64-69
- https://doi.org/10.1016/j.lungcan.2011.12.017
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals Of Oncology, 2006
- Current Approaches to Advanced-Stage Non–Small-Cell Lung Cancer: First-Line Therapy in Patients with a Good Functional StatusClinical Lung Cancer, 2006
- Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicityLung Cancer, 2005
- Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancerLung Cancer, 2004
- Gefitinib in Patients with Brain Metastases from Non–Small-Cell Lung Cancer: Review of 15 Clinical CasesClinical Lung Cancer, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factorsLung Cancer, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.Journal of Clinical Oncology, 1988